NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Shanghai Baoju

Published 12 Nov 2026. 35-page investigative report on who is behind Shanghai Baoju: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 101 Finnrick lab tests, Shanghai Baoju records 78 pass / 23 fail, an overall pass rate of 77%. The result is usable only product by product. GHK-Cu is the cleanest lane and Retatrutide is the stronger high-volume GLP-1 signal; KPV and TB-500 sit at the weak end and should not be treated as blind-buy products without independent lot testing.

The company story is less clean than the chemistry. Baoju’s current peptide storefronts trace to a short, layered public record: two main domains were registered ten seconds apart, share a WordPress administrator, and point to the same sales infrastructure, while an older archive of one domain belongs to an unrelated Jiangsu refinery-additives business. A removed supplier-platform profile and a LookChem trading-company listing complicate the claimed long operating history rather than confirming it.

Channel risk is a central finding. The report maps Baoju’s WordPress sites, the Ueeshop BaoJu Shop build, multiple UK/US/China messenger contacts, and a Henan Zhitai sales surface bridged by the Lucy/lucypeptide00 persona. It also documents parasite-SEO pages and a cloaked Baoju review doorway that served search crawlers one story while sending visitors to rotating WhatsApp numbers with a discount pitch; attribution is not proven, but impersonation risk is real.

Public sources reviewed identified sales staff and web administration, not the people responsible for sourcing, analytical review, QA, or batch release. Combined with no public COA portal, lot lookup, or anti-counterfeit workflow, that makes lot-level verification the practical buyer requirement even on Baoju’s better-tested products.

Inside the full report:

  • Per-product pass/fail analysis and methodology-divergence charts for all 9 tested products
  • RDAP and WordPress evidence tying baojuchemical.com and baojuchem.com to a common operator
  • Corporate-identity review covering GlobalSources, LookChem, Allbiz, registry dead ends, and address inconsistencies
  • Sales-persona and channel map across BaoJu Shop, Telegram, WhatsApp, TikTok, and the Zhitai-linked Lucy bridge
  • Parasite-SEO and cloaked-doorway analysis, including the peptides16/fzpefa WhatsApp funnel
  • Batch-traceability, COA-verification, and buyer-routing guidance by product lane

Risk assessment

  • KPV quality risk — high: KPV has 3 Finnrick tests with 0 pass / 3 fail and a 15.28% rating; avoid absent independent lot testing.
  • TB-500 quality risk — high: TB-500 has 4 tests with 1 pass / 3 fail and a 35.32% rating; avoid unless the exact lot is independently tested.
  • BPC-157 quality risk — medium: BPC-157 has 6 tests with 4 pass / 2 fail and a 54.75% rating; not a blind-buy product.
  • Tirzepatide quality risk — medium: Tirzepatide has 31 tests with 24 pass / 7 fail and a 78.17% rating; lot verification is essential for a dose-sensitive GLP-1.
  • Ipamorelin / Tesamorelin quality risk — medium: Ipamorelin has 5 tests with 3 pass / 2 fail and a 65.66% rating; Tesamorelin has 5 tests with 3 pass / 2 fail and a 50.5% rating.
  • Batch traceability and COA-verification risk — high: No public COA portal or lot lookup was found on the storefronts, and retained row-level captures show no-batch/unlabeled-vial descriptors.
  • Corporate-identity and history-claim risk — high: The 2005/25-year and factory-scale claims conflict with 2024 storefront registrations, an unrelated older baojuchem.com owner, self-reported supplier profiles, and unresolved registry records.
  • Channel and brand-confusion risk — high: Multiple Baoju/Zhitai storefronts, many sales personas, look-alike doorway domains, and no canonical official-channel list make impersonation hard to rule out.
  • High-toxicity / medically supervised catalog risk — high: Baoju-linked catalogs list DNP, clenbuterol, oral anabolic steroids, insulin, and Zhitai botulinum toxin, indicating weak safety boundary-setting beyond ordinary peptide QA.
  • Search-manipulation and cloaked-doorway risk — medium: Parasite-SEO pages and a cloaked WhatsApp funnel used the Baoju name; attribution is unproven, but the vendor provides no visible anti-impersonation guidance.